ATE314854T1 - Mittel zur prävention und/oder behandlung einer gewebeveränderung mesenchymalen ursprungs - Google Patents

Mittel zur prävention und/oder behandlung einer gewebeveränderung mesenchymalen ursprungs

Info

Publication number
ATE314854T1
ATE314854T1 AT00909001T AT00909001T ATE314854T1 AT E314854 T1 ATE314854 T1 AT E314854T1 AT 00909001 T AT00909001 T AT 00909001T AT 00909001 T AT00909001 T AT 00909001T AT E314854 T1 ATE314854 T1 AT E314854T1
Authority
AT
Austria
Prior art keywords
prevention
agents
treatment
mesenchymal origin
tissue
Prior art date
Application number
AT00909001T
Other languages
German (de)
English (en)
Inventor
Joern Bullerdiek
Original Assignee
Joern Bullerdiek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19904514A external-priority patent/DE19904514A1/de
Priority claimed from DE19943786A external-priority patent/DE19943786A1/de
Priority claimed from DE19943787A external-priority patent/DE19943787A1/de
Application filed by Joern Bullerdiek filed Critical Joern Bullerdiek
Application granted granted Critical
Publication of ATE314854T1 publication Critical patent/ATE314854T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00909001T 1999-02-04 2000-02-04 Mittel zur prävention und/oder behandlung einer gewebeveränderung mesenchymalen ursprungs ATE314854T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19904514A DE19904514A1 (de) 1999-02-04 1999-02-04 Mittel zur Prävention und/oder Behandlung von Leiomyomen
DE19943786A DE19943786A1 (de) 1999-09-13 1999-09-13 Mittel zur Prävention und/oder Behandlung von Gewebeveränderungen mesenchymalen Ursprungs
DE19943787A DE19943787A1 (de) 1999-09-13 1999-09-13 Mittel zur Prävention und/oder Behandlung von Gewebeveränderungen mesenchymalen Ursprungs

Publications (1)

Publication Number Publication Date
ATE314854T1 true ATE314854T1 (de) 2006-02-15

Family

ID=27218954

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00909001T ATE314854T1 (de) 1999-02-04 2000-02-04 Mittel zur prävention und/oder behandlung einer gewebeveränderung mesenchymalen ursprungs

Country Status (8)

Country Link
US (2) US20070202115A1 (enExample)
EP (1) EP1146881B1 (enExample)
JP (1) JP2002536345A (enExample)
AT (1) ATE314854T1 (enExample)
AU (1) AU776955B2 (enExample)
CA (1) CA2360942A1 (enExample)
DE (2) DE50012015D1 (enExample)
WO (1) WO2000045851A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102933594B (zh) 2009-10-07 2017-09-19 以色列农业与农村发展部，吉姆若恩兽医协会 布鲁氏菌噬菌体多核苷酸及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4285896A (en) * 1994-11-18 1996-06-19 Amira, Inc. Phosphinic creatine compounds having antiviral activity
US5972666A (en) * 1996-07-26 1999-10-26 G. D. Searle & Co. Assembly-deficient herpesvirus vaccine
GB9623522D0 (en) * 1996-11-11 1997-01-08 Pharmacia & Upjohn Spa Benzoheterocycle distamycin derivatives process for preparing them and their use as antitumour and antiviral agents
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives

Also Published As

Publication number Publication date
US20090304708A1 (en) 2009-12-10
US20070202115A1 (en) 2007-08-30
WO2000045851A2 (de) 2000-08-10
JP2002536345A (ja) 2002-10-29
WO2000045851A3 (de) 2000-12-28
EP1146881A2 (de) 2001-10-24
DE10080190D2 (de) 2002-01-24
CA2360942A1 (en) 2000-08-10
AU3145400A (en) 2000-08-25
DE50012015D1 (de) 2006-03-30
AU776955B2 (en) 2004-09-30
EP1146881B1 (de) 2006-01-04

Similar Documents

Publication Publication Date Title
DE60023043D1 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
ATE362374T1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
NZ517616A (en) Use of retigabin for treating neuropathic pain
ATE417602T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
ATE555803T1 (de) Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
PT1052905E (pt) Processo anti-germinativo de tuberculos e bolbos utilizando o eugenol e/ou o isoeugenol
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
ATE253351T1 (de) Desodoriende zubereitungen enthaltend wasserlösliche -(1,3)-glucane
DE69938179D1 (de) Kombination von riluzol und levodopa zur behandlung von morbus parkinson
ATE312079T1 (de) Nichtnukleoside reverse transkriptase-hemmer zur behandlung von hiv-infektion
ATE335499T1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
DE60139783D1 (de) Gen und pflanzenextrakte, wirksam zur behandlung und prävention von chlamydieninfektionen
DE60002226D1 (de) Zusammensetzung zur vorbeugung und/oder behandlung von kreislaufstörungen, enthaltend l-carnitin derivate und ginkgo biloba extrakte
DE69910202D1 (de) EGR-1 zur Herstellung eines Medikamentes zur Behandlung von Wunden
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
PL373528A1 (en) Medicine for preventing and treating bromidrosis
DK1133296T3 (da) Ny terapeutisk anvendelse af nicergolin
ATE314854T1 (de) Mittel zur prävention und/oder behandlung einer gewebeveränderung mesenchymalen ursprungs
DE60006519D1 (de) Glutathion-reduktase zur behandlung und prophylaxe von aids
ES2190581T3 (es) 2-aminotetralina opticamente activa, procedimiento para su preparacion y composiciones farmaceuticas que la contienen, activa en la prevencion y tratamiento de shock septico.
ATE275949T1 (de) Verwendung von diminazen-di-aceturat und/oder pentamidin zur behandlung von malaria
DE69919578D1 (de) VERWENDUNG von NIEDERMOLEKULAREM HEPARIN zur Behandlung und/oder Prophylaxe motoneuronaler Krankheiten
ATE412423T1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
DE60043936D1 (de) Vorbeugung und behandlung von p. gingivalis infektion
ATE270542T1 (de) Zusammensetzung zur verhinderung der keimbindung

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee